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Abstract
As part of analgosedative treatment modalities after delivery (e.g. 
caesarean related pain, birth related trauma, pre-existing pain syndromes), 
mothers are treated with different analgosedatives that may also affect the 
nursing infant. This review aims to summarize the available knowledge on 
commonly prescribed analgosedatives (opioids, intravenous and inhalational 
anesthetics, benzodiazepines, non-opioid analgesics, and local anesthetics) 
during breastfeeding. 
We propose that the use of systemic non-opioid analgesics, local 
anesthetics, inhalational or intravenous anesthetics is safe when mothers 
are nursing. When systemic opioids are used, we recommend pediatricians 
to consider clinical monitoring of the infant for sedation. The duration of 
maternal exposure (> 4 days) and the presence of maternal signs of somnolence 
are hereby of additional relevance. We encourage research groups to report 
on their specific observations and expertise in order to further validate the 
current practices and guidance.
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Introduction
Most drugs are not extensively evaluated during 
pregnancy or postpartum, including the setting of 
breastfeeding [1-3]. This is to a large extent similar 
to the off-label and unlicensed pharmacotherapy 
in neonates and children. Consequently, the label 
commonly mentions a default setting that “the 
drug has not been studied during pregnancy or 
breastfeeding”. Despite this, nursing women often 
need pharmacological treatment for a range of 
conditions. The ultimate goals of maternal drug 
use during breastfeeding are dual. First, this should 
provide effective and safe therapy for the maternal 
condition(s) (e.g. postpartum maternal analgesia, 
maternal co-morbidities, pregnancy related dis- 
eases). Simultaneously, we also aim to assure the 
safety for the nursing infant from (relevant) adverse 
events related to the maternal treatment [1-3]. Only 
very rarely, these goals overlap (e.g. maternal 
galactagogues intake to induce milk production, 
like metoclopramide or domperidone) [4]. 
In essence, exposure of a nursing mother to 
any dose of drug (maternal dose, D
m
) will result 
in – be it very limited – transfer of the drug into 
the human milk (estimated infant dose, D
i
). 
However, concentrations reached in the human milk 
are usually quite low and oral bioavailability in the 
infant should also be considered before any relevant 
pharmacological exposure (relative infant dose, 
RID = D
m
/D
i
 * absorption) and effect in the infant 
needs to be anticipated (Fig. 1). The difference in 
drug concentration in the infant’s plasma (a vs b) can 
be explained by the presence (a) or absence (b) of 
“initial loading related to fetal exposure to the same 
compound before delivery” [5, 6]. Age also matters, 
since the newborn seems to be more vulnerable to 
adverse effects when compared to infants and refers 
to the age-related changes in pharmacokinetics 
or -dynamics [7]. In essence, most drugs appear 
in mother’s milk, but the final concentration time 
profiles in the infant depend on the concentration 
in the milk, the bio-availability, clearance capacity 
and the initial concentration (fetal + neonatal or only 
neonatal exposure). Finally, accumulation relates to 
the duration of exposure and the initial concentration 
in the newborn. In the setting of continuation 
of treatment of the mother from pregnancy to 
postpartum, the fetus will likely already be exposed 
to the maternal drugs, and the newborn will already 
Figure 1. Maternal-infant pharmacokinetics in the setting of exposure through breastfeeding. The difference in drug 
concentration in the infant’s plasma (a vs b) can be explained by the presence (a) or absence (b) of “initial loading related 
to fetal exposure to the same compound before delivery” [5, 6]. 
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have an initial concentration of this compound at 
birth. The subsequent concentration will depend 
on the amount of exposure, the clearance capacity 
and the distribution volume characteristics (e.g. 
postnatal weight evolution) [5-7]. 
Despite the fact that lactating women are regular 
users of medications and that women are often 
advised to discontinue or stop nursing while taking 
the drug, there are only a limited number of drugs 
that have been identified as potentially harmful to the 
newborn [5, 6]. Using a prospective study design, Ito 
et al. documented in a cohort of 838 nursing infants 
with mothers taking medications that the incidence 
of adverse reactions was 11.2% (94/838) [8]. All 
these events were classified as minor reactions, not 
necessitating medical attention. Antibiotics (19.3%), 
antihistamines (9.4%), sedatives, antidepressants 
or anti-epileptics (7.1%), but also analgesics, 
including narcotics (11.2%) were most commonly 
associated with adverse reactions. The reported 
adverse reactions were diarrhea (antibiotics), 
drowsiness (analgesics, sedatives, antidepressants, 
antiepileptics) or irritability (antihistamines) [8]. 
The incidence, the type of reactions and compounds 
associated are in line with the systematic literature 
review performed by Anderson et al. [5]. Based on 
the evaluation of 100 published case reports, none 
were considered to be “definite” using a standard 
ranking scale, 47% were “probable”, 53% were 
“possible”. However, drugs with central nervous 
system activity accounted for about 50% of the 
events [5]. 
These data suggest that breastfeeding rarely 
needs to be discouraged or discontinued when a 
mother needs drug therapy, but some cautiousness 
about analgosedatives may be warranted [5, 6, 8]. 
As part of analgosedative treatment modalities after 
delivery (e.g. caesarean related pain, birth related 
trauma, pre-existing pain syndromes), mothers 
are exposed to different analgosedatives that may 
affect the nursing infant. This review aims to 
summarize the available knowledge on commonly 
prescribed analgosedatives (opioids, intravenous 
and inhalational anesthetics, benzodiazepines, non-
opioid analgesics, and local anesthetics) during 
breastfeeding. 
Compound specific observations
Opioids
The rate of breastfeeding has increased again 
steadily in the developed world [9, 10]. During 
Analgosedatives and breastfeeding
this time, opioid use in the general population 
steadily increased as well. This means that the 
clinical experience with maternal opioids is still 
fairly limited with emerging data on (side)effects 
with codeine, oxycodone, methadone and tramadol 
during nursing [6, 11]. Opioid absorption after 
oral ingestion in neonates should be anticipated, 
while the extent of exposure through mother’s 
milk will depend on maternal ingestion (dose) 
and metabolism. Neonatal clearance relates to the 
neonate’s metabolic or renal elimination, and will 
be limited [7]. Such a setting has the potential to 
result in unanticipated side effects in individual 
cases. 
A pivotal case report in 2006 of Koren et al. 
on codeine related poisoning in a newborn through 
breastfeeding reactivated the clinical research on 
maternal-infant opioid pharmacokinetics [12]. A 
pharmacogenetic link between maternal ultrafast 
metabolizer status for cytochrome p450 (CYP) 
2D6 was documented, since this results in higher 
and faster conversion of codeine to morphine 
[12]. More recently, the same group documented 
that a combination of different maternal genetic 
polymorphisms (i.e. CYP 2D6 and P-glycoprotein 
polymorphisms) predicted 87% of the infant and 
maternal central nervous system depression cases 
with a sensitivity of 80% and a specificity of 87% 
in a cohort of 111 breastfeeding mother-infant 
pairs [13]. 
The incidence of central nervous system 
depression in breastfed neonates following maternal 
exposure to oxycodone, codeine or paracetamol 
was retrospectively compared in 533 mother-infant 
pairs. Lam et al. hereby clearly showed that there 
was a 20.1% rate of depression in infants of nursing 
mothers on oxycodone, as compared with 16.7% 
and 0.5% when treated with codeine or paracetamol 
[14]. Methadone is somewhat an outlier, since 
commonly used in a setting of maternal opioid 
addiction. Consequently, these neonates are already 
exposed to methadone in fetal life. Methadone is 
excreted into human milk (2-3% of weight-adjusted 
maternal dose), and there are data that suggest that 
these infants benefit from breastfeeding (blunted 
opioid withdrawal syndrome), hereby confirming 
an exposure/effect relation. Breastfed babies less 
commonly display neonatal abstinence syndrome 
and, if needed, the cumulative dose of methadone 
is lower and the length of hospital stay is shorter 
[6]. Finally, using a sparse sampling study design 
to assess transfer of tramadol and O-desmethyl 
tramadol into transitional breast milk, the relative 
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infant dose of 2-3% remained very limited. Based 
on these observations, the authors concluded that 
short-term maternal use of tramadol is compatible 
with breastfeeding [15].
There are also some additional clinical useful 
observations on maternal codeine and oxycodone 
exposure for the pediatrician. First, there is high 
concordance between maternal and neonatal 
somnolence. When the mother exhibits somnolence, 
the baby should be examined by a pediatrician. 
Secondly, severe somnolence commonly emerged 
after 4 days of use, when milk output increases, 
exposure increases and is prolonged. Therefore, any 
maternal need for opioids for more than 4 days after 
delivery warrants additional evaluation [16-18].
Obviously, there are major differences when 
opioids are administered by either systemic (oral, 
intravenous, transcutaneous) routes compared to 
loco-regional anesthesia. To illustrate this, we refer 
to the estimations of infant exposure in a setting 
of patient (maternal) controlled epidural pethidine 
administration [19]. The combined absolute infant 
dose of pethidine and norpethidine received via 
milk was 1.8% of the neonatal therapeutic dose 
and the combined relative infant dose was below 
the 10% recommended safety level. Based on these 
data, the authors concluded that breastfed infants 
are at low risk of relevant drug exposure in the 
setting of patient-controlled epidural pethidine [19]. 
The interaction between locoregional analgesia and 
breastfeeding outcome goes beyond drug exposure 
through breastfeeding, and we refer the interested 
reader to some reviews on this topic [20, 21]. 
Intravenous and inhalational anesthetics
Although the number of observations is limited, 
excretion of propofol in human milk does not equal 
infant exposure (Fig. 1) [22, 23]. This is because 
enteral absorption is the rate limiting factor. The 
same holds true for inhalational agents in postpartum, 
but buccal etomidate resorption has been observed. 
Obviously, this rationale only applies when these 
compounds are administered after delivery, since 
when administered during labor or before delivery, 
placental passage may result in fetal accumulation 
and subsequent effects [22]. 
Benzodiazepines 
Lorazepam, midazolam or diazepam are 
commonly administered as anxiolytic. These 
compounds and some of their metabolites can be 
retrieved in human milk but concentrations remain 
very limited [22-24]. In 24 hours of human milk 
collection after a single dose, only 0.005% of the 
maternal midazolam dose was retrieved. Taking 
the subsequent oral bio-availability (50-60%) into 
account, it is very reasonable to assume that the 
exposure will be limited when administered after 
delivery. In contrast, plasma diazepam and its active 
metabolite (desmethyldiazepam) could be measured 
up to 7-10 days of postnatal age in neonatal plasma 
samples after administration to the mother before 
delivery [24]. 
Non-opioid analgesics 
Human milk and plasma paracetamol levels 
were monitored in 3 lactating women after ingestion 
of 500 mg dose of paracetamol in the postpartum 
period. Paracetamol concentrations remained lower 
in human milk (milk/plasma ratio of 0.76). Since 
less than 0.1% of the maternal dose would be present 
in 100 ml milk, nursing should not be discontinued 
following maternal paracetamol exposure [25]. 
Similarly, ibuprofen in human milk and serum was 
quantified in 12 patients who had ingested one 400 
mg tablet of ibuprofen every 6 hours over a 24 hour 
period immediately following delivery (relief post-
caesarean pain). Ibuprofen could not be quantified 
in human milk [26]. Based on the lower limit of 
quantification (1 µg/ml), less than 1 mg of ibuprofen 
per day is excreted in breast milk. Similar findings 
have been described for ketorolac [27]. Even if 
these compounds result in exposure, the extent will 
remain limited and much lower than that clinical 
registered dosing for analgesia or temperature 
reduction [28].
Local anesthetics 
Local anesthetics (including lidocaine, ropiva- 
caine, and bupivacaine) are commonly adminis- 
tered as part of regional anesthetic techniques (e.g. 
regional pain block, epidural) and data are mainly 
available in mothers during labor or for anesthesia 
[29]. Data on excretion of lidocaine and bupivacaine 
in human milk have been reported. To illustrate 
this, we refer to a paper of Giuliani et al. [30]. The 
authors quantified lidocaine and its metabolite 
(monoethyl-glycinexylidide, MEGX) disposition in 
7 nursing mothers (23-39 years, 3.6 to 7.2 ml 2% 
lidocaine without adrenaline, dental care). Based 
on these observations, the daily infant exposure to 
lidocaine and MEGX were 73.41 ± 38.94 µg/L/day 
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and 66.1 ± 28.5 µg/L/day. Moreover, absorption 
following oral ingestion is limited. Based on the 
available evidence, the exposure is limited with 
minor statistical significant, but clinical irrelevant 
effects.
Discussion
There is an increase in breastfeeding, supported 
by – among others – the Baby Friendly Hospital 
initiative. Consequently, women also want to 
breastfeed shortly following analgosedation [9, 10, 
23]. In general, the short-term use of these drugs 
already limits the risks of these effects, while 
prolonged exposure should increase our vigilance. 
Based on the observations retrieved in litera- 
ture, the use of systemic non-opioid analgesics, 
local anesthetics, and inhalational or intravenous 
anesthetics seems safe for nursing mothers. 
When systemic opioids are used, we recommend 
pediatricians to consider some clinical monitoring 
with specific emphasis on the duration of 
exposure (4 days pivotal) and the presence of 
any maternal sign (somnolence) [16]. Finally, the 
use of benzodiazepines should be limited with 
preference to those with shorter half-life. Under 
these circumstances, the most appropriate advice 
to a nursing mother undergoing anesthesia is that 
she may reinitiate breastfeeding when she feels 
sufficiently alert to do so. 
Obviously, the knowledge on clinical pharma- 
cology during breastfeeding evolves rapidly and 
has become a field of active clinical research. This 
means that updated, reliable information should 
be easy accessible. Besides textbooks, LactMed is 
a free online database with information on drugs 
and lactation as one of the newest additions to the 
National Library of Medicine’s TOXNET system 
[31]. Similarly, the Motherisk program also has an 
updated and useful website that can be searched, 
and is open for advice [32]. We encourage research 
groups to report on their specific observations and 
expertise in order to further validate the current 
practices. 
Neonatal abstinence syndrome (NAS) following 
prolonged maternal exposure to opioids is a separate 
setting that warrants a tailored, specific approach 
[33]. As part of such a tailored approach, there are 
data that suggest that breastfeeding reduces the 
incidence and duration of NAS [33-36]. Based on 
a pooled dataset of 400 neonates (218 breastfed, 
54.5%), there is a significant reduction in NAS (54% 
vs 77%, number needed to treat 5-6). The same trends 
are observed when the duration of opioid treatment 
(18 to 23 days) or the length of hospital stay (4 to 10 
days) are considered [34-36]. Another benefit with 
this approach is that administering methadone to 
the neonate and young infant through breastfeeding 
results in much more gradual exposure to this drug 
and prevent inadvertent dosing. The major limitation 
of the above mentioned observational studies is 
bias. All studies reported that breastfed neonates 
required less pharmacological interventions and 
had shorter hospital stays. However, these effects 
may be due to confounding (i.e. breastfeeding is just 
a “marker”) factors. Among others, these could be 
better adherence, less psychological co-morbidity, 
or differences in staff attitudes towards nursing 
women [37].
Conclusions
In conclusion, the use of systemic non-opioid 
analgesics, local anesthetics, inhalational or 
intravenous anesthetics seems safe when mothers 
are nursing. When systemic opioids are used, we 
recommend pediatricians to consider some clinical 
monitoring with specific emphasis on the duration 
of exposure and the presence of any maternal sign 
(somnolence). We encourage research groups to 
report on their specific observations and expertise 
in order to further validate the current practices and 
guidance.
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